Table 2.
Effect and side effects in the two groups.
| Effect and side effects | Eso20 | PRA | Statistics |
| Overall satisfaction with the treatment (no) | 36 (92%) | 22 (58%) | p = 0.001 |
| Weeks of satisfactory relief (mean proportion) | 89% (26) | 62% (44) | p = 0.008 |
| Symptom score at the end of treatment (mean) | 5.9 (3.4) | 8.0 (4.4) | p = 0.019 |
| Preference for same drug after the trial (no) | 33 (85%) | 16 (42%) | P < 0.001 |
| Preference for regular treatment (no) | 6 (15%) | 6 (16%) | ns (p = 1.00) |
| Diarrhoea (no) | 1 (3%) | 6 (16%) | ns (p = 0.056) |
| Too many tablets (no) | 2 (6%) | 11 (29%) | p = 0.006 |
| Delayed onset of effect (no) | 10 (26%) | 4 (11%) | ns (p = 0.14) |
| Rapid relapse of symptoms (no) | 8 (21%) | 18 (47%) | p = 0.017 |
The results are given as number of patients (proportion in brackets) or mean (standard deviation in brackets).
Eso20: Esomeprazole 20 mg.
PRA: Pectin-based Raft-forming Agent.